Table 5.

Wastage-adjusted MR-MAP price thresholds (2020 US$) for introducing MR-MAPs to be cost-effective

Projection assumption	Higher coverage		Lower coverage
Introduction strategy	Sequential	Accelerated	Sequential	Accelerated
Low income
Income group level	0.764	0.709	5.89	5.47
Country level	0.123–2.32 (n=19)	0.041–2.51 (n=19)	0.397–18.1 (n=19)	0.586–18.1 (n=19)
Lower middle income
Income group level	2.67	2.17	14.7	11.6
Country level	0.012–37.9 (n=25)	0.051–40.7 (n=27)	0.086–39.6 (n=31)	0.572–72.0 (n=29)
Upper middle income
Income group level	23.9	27.4	76.6	67.2
Country level	0.658–353 (n=10)	0.635–389 (n=9)	0.586–3310 (n=12)	0.579–1730 (n=12)

Numbers represent the wastage-adjusted price thresholds for introducing MR-MAPs to be cost-effective at the income group level and the country level under different coverage projection assumptions and introduction strategies. At the country level, the ranges of price thresholds are presented, with n in the brackets denoting the number of countries except for those where introducing MR-MAPs will not be cost-effective even if the procurement of MR-MAPs is at zero cost. The price thresholds were calculated while the health burden estimates, vaccine wastage rates and other cost inputs were assumed fixed. If an MR-MAP dose is provided at a procurement price above the threshold, it implies that introducing MR-MAPs would not be cost-effective.

MR-MAP, measles-rubella microarray patch.